Biocon has received approval from the U.S. Food and Drug Administration (US FDA), for its vertically integrated, complex injectable drug product, Micafungin (50mg and 100mg vials), used as an antifungal medication to treat fungal or yeast infections. The approval further strengthens Biocon’s portfolio of vertically integrated, complex drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
